ELVN Options (ELVN20260515P35) Price & Quote

Symbols

--(--)

Expected P&L on Expiry

Key Stats

0.00DAY`S RANGE0.00

Open

0.00

Prev.Close

0.00

Turnover

Volume

Premium

Extrinsic Value

Open Interest

Intrinsic Value

Pricing Model

Delta

Gamma

Theta

Vega

Rho

Theor Price

About ELVN20260515P35

Underlying

Enliven Therapeutics, Inc.

Industry

Pharmaceutical

Introduction

Enliven Therapeutics, Inc., was incorporated in Delaware in June 2019. This clinical-stage biopharmaceutical company focuses on the discovery and development of small molecule therapeutic drugs to help people not only live longer, but live better. The Company addresses existing and emerging unmet needs through a precision medicine approach that improves survival and enhances overall well-being. Its discovery process combines deep insights and differentiated chemistry on clinically proven biological targets with the goal of designing therapies that meet these unmet needs. By combining clinically validated targets and specific target product features with rigorous clinical trial design and regulatory strategies, we are committed to developing drugs that effectively meet unmet needs and increase the likelihood of clinical and commercial success. Currently, the company is advancing ELVN-001 and exploring multiple additional research stage opportunities consistent with its small molecule development strategy.